Tom 8, Nr 1 (2023)
Artykuł przeglądowy
Opublikowany online: 2023-02-17

dostęp otwarty

Wyświetlenia strony 2500
Wyświetlenia/pobrania artykułu 97
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

The challenges of oncogerontology

Krzysztof Jeziorski12
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2023;8(1):18-21.

Streszczenie

Oncogerontology is a term that describes an interdisciplinary discipline dealing with the broadly understood relationship between oncology and human aging. The problems that pose a challenge for oncogerontology include, among others, the deteriorating cancer epidemiological situation, as well as the impact of the COVID pandemic on this situation, age restriction of screening tests in the elderly and the inequalities for older patients in accessing medical services and their participation in clinical trials. Data from the National Cancer Registry show an increase in the incidence and mortality of malignancies, especially in the elderly population. The epidemiological situation of cancer in Poland has been nega­tively affected by the COVID pandemic. New EU recommendations increase the number and quality of screening tests in the elderly. This group of patients has limited access to some oncological services and clinical trials. Artificial intelligence is an opportunity to improve diagnostics, therapy and oncology care in older patients.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Kenig J. Oncogeriatrics (part 1.). Frailty in older adults with cancer. Nowotwory. Journal of Oncology. 2019; 69(2): 55–57.
  2. Didkowska J. Epidemiologia nowotworów osób starszych. In: Broczek K, Dubianski R. ed. Onkologia geriatryczna w praktyce. Ed.1. Medical Tribune Polska, Warszawa 2022: 43–53.
  3. Didkowska J, Wojciechowska U, Olasek P, et al. Cancer in Poland in 2019. http://onkologia.org.pl/wp-content/uploads/Nowotwory_2019.pdf.
  4. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Tomorrow. International Agency for Research on Cancer, Lyon 2018. https:// gco.iarc.fr/tomorrow (26.09.2020).
  5. Santucci C, Patel L, Malvezzi M, et al. Persisting cancer mortality gap between western and eastern Europe. Eur J Cancer. 2022; 165: 1–12.
  6. Patt D, Gordan L, Diaz M, et al. Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. JCO Clin Cancer Inform. 2020; 4: 1059–1071.
  7. Koczkodaj P, Sulkowska U, Kamiński M, et al. SARS-CoV-2 as a new possible long-lasting determining factor impacting cancer death numbers. Based on the example of breast, colorectal and cervical cancer in Poland. Nowotwory. Journal of Oncology. 2021; 71(1): 42–46.
  8. Olszewski R, Obiała J, Obiała K, et al. One year into COVID-19 – the infodemiology of cancer screening. Nowotwory. Journal of Oncology. 2022; 72(3): 195–199.
  9. European Commission. Directorate-general for Health and Food safety. Proposal for a Council recommendation (CR) on strengthening prevention through erly detection: a new approach on cancer screening replacing Council Recommendation 2003/878/EC. 20 September 2022. http://com_2022-474_act_en.pdf.
  10. Malik MK, Tartter PI, Belfer R. Undertreated breast cancer in the elderly. J Cancer Epidemiol. 2013; 2013: 893104.
  11. Le Saux O, Falandry C, Gan HK, et al. Inclusion of elderly patients in oncology clinical trials. Ann Oncol. 2016; 27(9): 1799–1804.
  12. Baldini C, Charton E, Schultz E, et al. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study. ESMO Open. 2022; 7(3): 100468.
  13. Leonard R, Ballinger R, Cameron D, et al. Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase? Br J Cancer. 2011; 105(9): 1260–1266.
  14. Whelehan S, Lynch O, Treacy N, et al. Optimising Clinical Trial Design in Older Cancer Patients. Geriatrics (Basel). 2018; 3(3).
  15. Herrera AP, Snipes SA, King DW, et al. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010; 100 Suppl 1(Suppl 1): S105–S112.
  16. Yuval R, Uziel K, Gordon N, et al. Perceived benefit after participating in positive or negative/neutral heart failure trials: the patients' perspective. Eur J Heart Fail. 2001; 3(2): 217–223.
  17. Townsley CA, Chan KK, Pond GR, et al. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer. 2006; 6: 34.
  18. Estapé T. Cancer in the Elderly: Challenges and Barriers. Asia Pac J Oncol Nurs. 2018; 5(1): 40–42.



Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory